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Brain-derived neurotrophic factor (BDNF) Val66Met genotype has been associated with neurobehavioral deficits. To
examine its relevance for addiction, we examined BDNF genotype differences in drug-seeking behavior. Heroin-
dependent volunteers (n = 128) completed an interview that assessed past-month naturalistic drug-seeking/use
behaviors. In African Americans (n = 74), the Met allele was uncommon (carrier frequency 6.8%); thus, analyses
focused on European Americans (n = 54), in whom the Met allele was common (carrier frequency 37.0%). In their
natural setting, Met carriers (n = 20) reported more time- and cost-intensive heroin-seeking and more cigarette use
than Val homozygotes (n = 34). BDNF Val66Met genotype predicted 18.4% of variance in ‘weekly heroin investment’
(purchasing time ¥ amount ¥ frequency). These data suggest that the BDNF Met allele may confer a ‘preferred drug-
invested’ phenotype, resistant to moderating effects of higher drug prices and non-drug reinforcement. These prelimi-
nary hypothesis-generating findings require replication, but are consistent with pre-clinical data that demonstrate
neurotrophic influence in drug reinforcement. Whether this genotype is relevant to other abused substances besides
opioids or nicotine, or treatment response, remains to be determined.
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Genetic association studies of addictive disorders typi-
cally attempt to identify polymorphisms underlying
initial vulnerability (e.g. Enoch et al. 2009; Saccone et al.
2009; Yuferov et al. 2010). Yet, genetic influences may
operate at various stages of the addiction cycle (Li & Bur-
meister 2009; Khokhar et al. 2010). Little is known
about which biologically plausible functional genotypes
alter persistence of addictive behaviors. Improved knowl-
edge could help predict resistance to, or benefit from,
treatments. Unlike studies of vulnerability, genetic
studies of addictive persistence target individuals who are
already drug-dependent because the goal is to under-
stand genotypic and phenotypic heterogeneity within the
clinical population.
Substance use disorders are complex syndromes that
are not ideally suited for genetic studies (Wong &
Schumann 2008). Phenotype selection requires a tar-
geted approach (Gottesman & Gould 2003; Ducci &
Goldman 2008; Lerman, Perkins & Gould 2009). Assess-
ing an intermediate phenotype (versus a broader pheno-
type such as a nosological condition) is preferable
because a circumscribed measure will tend to be more
reliable (which improves power to find associations with
the genotype) and perhaps more closely related to genetic
underpinnings than a multifactor syndrome. In the
present research, we selected drug-seeking behavior
(intermediate phenotype) by heroin-dependent, out-of-
treatment volunteers because (1) individual drug-
seeking patterns are periodic (within days) and stable
(between days) due to physical dependence and motiva-
tion to avoid opioid withdrawal signs/symptoms (Koob
and Le Moal, 2001); and (2) this characteristic pattern
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enables investigation to focus on predictive validity, i.e.
whether genetic heterogeneity within this group explains
phenotypic variance. Our approach emphasizes the drug
user’s habitual purchasing costs (time andmoney), which
capture behavioral investment in this drug-seeking reper-
toire. We control for enabling environmental factors (e.g.
income, drug cost and supply), which are presumably
orthogonal to genetic influence. Finally, because cigarette
smoking is highly prevalent among heroin-dependent
individuals, we examined whether genotypic effect is
limited to opioid-seeking behavior or may also apply to
nicotine-reinforced behavior (as cigarette smoking also
follows a highly period and stable pattern), i.e. behavioral
specificity.
Brain-derived neurotrophic factor (BDNF) is the most
widely distributed neurotrophin and is involved in neuro-
genesis, differentiation, survival and synaptic plasticity
(Lu 2003; Lipsky & Marini 2007; Russo et al. 2009).
BDNF secretion is activity-dependent—e.g. increased by
cognition and exercise, and decreased by stressors—and
modulates neurotransmission in dopamine, glutamate,
gamma-aminobutyric acid and serotonin systems (e.g.
Goggi et al. 2002; Carvalho et al. 2008). The human
BDNF gene encodes a 247 amino acid pre-protein (pro-
BDNF) that is cleaved to form an evolutionarily conserved
120 amino acid mature protein (Maisonpierre et al.
1991). A single nucleotide polymorphism (SNP; rs6265)
results in methionine substitution for valine at codon 66
(Val66Met). The evolutionarily recent, less-frequent Met
allele alters the pro-BDNF protein sequence, which dis-
rupts trafficking and results in less activity-dependent
BDNF secretion without affecting the mature BDNF
sequence (Egan et al. 2003; Lu 2003; Chen et al. 2004).
As might be expected from its neurotrophic physi-
ological influence, the BDNF Val66Met genotype has
unsurprisingly been associated with pleiotropic effects.
Met allele carriers exhibit several reliable intermediate
phenotypes: reduced gray matter volume in the hippoc-
ampus (Pezawas et al. 2004; Szeszko et al. 2005; Bueller
et al. 2006; Frodl et al. 2007 [European/Caucasian]) and
dorsolateral prefrontal cortex (e.g. Hariri et al. 2003),
and impaired hippocampal-dependent memory function
(Egan et al. 2003; Hariri et al. 2003 [Caucasian]). In the
realm of substance use, the BDNF 66Met allele has been
associated with headache-related overuse of non-opioid
analgesics (Di Lorenzo et al. 2008), increased risk of
nicotine dependence (Lang et al. 2007 [German]) and
earlier onset of alcohol dependence (Matsushita et al.
2004 [Japanese]), but decreased risk of dependence on
heroin (Cheng et al. 2005 [Han Chinese]) and protection
against post-treatment alcohol relapse (Wojnar et al.
2009 [Polish]). Met allele frequency and informativeness
varies significantly by ancestry, with highest prevalence
in Asians, moderate prevalence for Europeans and lowest
among American Indians and individuals of African
descent (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?
rs=rs6265; Petryshen et al. 2010). Accordingly, associa-
tion studies should test phenotypic relationships with the
BDNF Val66Met genotype within clearly defined ancestral
groups.
In addition to the above evidence that the Val66Met
genotype has neurobiological and clinical relevance, find-
ings fromanimal studies further suggest that BDNF physi-
ology influences opioid-dependence behaviors. Chronic
opioid exposure alters BDNF/TrkB receptor-mediated
dopamine function in the ventral tegmental area (VTA;
Bolanos &Nestler 2004; Russo et al. 2009) and its projec-
tion to the nucleus accumbens, the key neural circuitry
underlying opioid reinforcement. Experimental infusions
of BDNF directly into the VTA produce drug-seeking (Lu
et al. 2004) and biochemical changes (Berhow et al.
1995; Sklair-Tavron et al. 1996; Vargas-Perez et al.
2009). Discontinuation of chronic opioid exposure leads
to increased BDNF mRNA expression in brain regions
underlying physical dependence and drug-seeking
(Numan et al. 1998; Hatami et al. 2007). BDNF mRNA
expression in prefrontal cortex is upregulated following
exposure to psychostimulants and morphine, but to a
lesser extent with nicotine (Le Foll, Diaz & Sokoloff 2005).
Given that the BDNF 66Met allele has been linked to
impaired hippocampal and frontal-cortical morphology
and learning/memory problems, and thus impaired behav-
ioral flexibility, we theorized that the Met allele might
confer resistance to environmentally or pharmacologically
induced changes in drug-seeking/use. If true, then the Met
allele could have opposite effects at different stages of
addiction, i.e. protecting against initial vulnerability
(thus explaining counterintuitive results by Cheng et al.
2005) while making it more difficult to modify chronic
drug-seeking/use (i.e. harder to unlearn). Thus, we asked:
Do heroin-dependent Met allele carriers exhibit greater
drug-seeking behavior in the context of non-drug envi-
ronmental alternatives? Our aim was to determine the
extent of BDNF Val66Met associations with behavioral
investment in opioid-seeking.
MATERIALS AND METHODS
Participants
This investigation encompasses three source studies
approvedby InvestigationalReviewBoardsatWayneState
University and the University of Michigan (for method-
ological details, see Greenwald &Hursh 2006; Greenwald
& Steinmiller 2009; Greenwald 2010), and conducted in
accordance with the Declaration of Helsinki. Certificates
of confidentiality were obtained from the National Insti-
tute on Drug Abuse. Male and female volunteers, 18–55
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yearsold,were recruited fromtheDetroit areausingnews-
paperadsandword-of-mouth. Ethnicityandracewerenot
exclusion factors, but, due to low frequency of other
racial/ethnic groups, only African American (AA) and
European American (EA) subjects were included in the
present data analyses. Those identifying themselves as
heroin-dependent and not seeking treatment were
instructed to call for a telephone interview.
The screening process included informed consent,
providing demographic data, comprehensive substance
use and medical histories, and an interview lasting
20–30 minutes that was used to obtain specific data
about past-month income, drug purchasing and use
factors (see below). All participants reported current
daily heroin use, provided a urine sample that was posi-
tive for opioids (> 300 ng/ml), and were diagnosed with
current opioid dependence based on clinician interview
using Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition (DSM-IV) criteria. Urine samples
were also tested for methadone, cocaine, benzodiaz-
epines, cannabinoids and barbiturates. Volunteers had to
provide an alcohol-free breath sample (< 0.002%). Par-
ticipants were paid $30 for completing the first screening
visit, and those who continued in screening toward quali-
fying for laboratory-based studies could earn $25 more
over two subsequent screening visits.
Genotyping
The Golden Gate drug addiction Illumina panel
(Hodgkinson et al. 2008) was used to genotype blood
samples provided by each participant. Whole blood
(6 ml/subject) was collected into ethylenediaminetet-
raacetic acid tubes and DNAwas extracted using Oragene
DNA self collection kit (Qiagen, Valencia, CA, USA) (for-
merly Gentra Puregene kit).
Due to the relatively rare BDNF rs6265Met/Met geno-
type (see Table 1), all analyses contrasted Met carriers
(Met/Met + Met/Val) with Val homozygotes. To examine
the specificity of the BDNF rs6265 polymorphism, four
BDNF variants with relatively high minor allele frequen-
cies (> 0.25) located in the 3′ untranslated (UTR) region
(rs1519480, rs7124442, rs7934165 and rs11030121)
were also included in the analyses. All of these 3′ UTR
SNPs were in linkage disequilibrium (LD) with the
functional SNP (rs6265), and all were in LD with each
other. Furthermore, none of the 3′ UTR SNPs was sig-
nificantly related to the phenotypes tested here. For this
reason, these 3′ UTR SNPs are not mentioned further.
Phenotyping measures
Phenotypes were derived from a semi-structured inter-
view that was previously validated with heroin abusers
(Roddy & Greenwald 2009; Roddy, Steinmiller & Green-
wald 2011). Participants were asked a series of interre-
lated questions to ascertain past-month sources and
amounts of income (legal and illegal), heroin price, esti-
mated purity, all drug and non-drug expenditures, drug-
acquisitive behaviors (e.g. purchase time, amount spent
and purchasing frequency) and heroin consumption (e.g.
bags per day, including the distribution of use through-
out the day). To examine the behavioral specificity of
BDNF genotype on drug-seeking, we also ascertained
daily cigarette use, alcohol use and illegal drug use as part
of a comprehensive substance use history questionnaire.
Data analyses
BDNF Val66Met genotype and allelic distributions were
computed for each ancestral group (Table 1). Genotype
frequencies were tested for Hardy–Weinberg equilibrium
using a web-based calculator (http://scienceforall.org/
2010/06/20/hardy-weinberg-equilibrium-calculator/).
Analyses were conducted using SPSS v.19 (SPSS Inc.,
Chicago, IL, USA). BDNF genotype comparisons on cat-
egorical variables [other BDNF genotypes, race, gender,
route of heroin use (injection versus non-injection), ever
overdosed on heroin, and lifetime psychiatric diagnoses]
were performed using c2 tests. BDNF genotype compari-
sons for continuous variables were conducted using one-
way analysis of variance (ANOVA; Table 2). Descriptive
statistics are presented as means  1 standard deviation
(SD). For all analyses, the criterion for null hypothesis
rejection was set at nominal P < 0.05.
Variables that were not normally distributed (see
below) were log10-transformed for correlation and regres-
sion analyses. See Figure 1 for distributions of heroin-
purchasing measures. We conducted tests of BDNF
genotype effect for key measures of drug-seeking/use
behavior, and for control variables that—while not
hypothesized as related to the genotype—might need to
Table 1 Brain-derived neurotrophic factor
Val/Met genotype distributions and allele
frequencies [% within group (row)].
Genotype (n) Met/Met Met/Val Val/Val Minor allele Major allele
rs6265 A/A A/G G/G A (Met) G (Val)
Black (74) 0 (0.0) 5 (6.8) 69 (93.2) 5 (3.4) 143 (96.6)
White (54) 3 (5.6) 17 (31.5) 34 (63.0) 23 (21.3) 85 (78.7)
Overall (128) 3 (2.3) 22 (17.2) 103 (80.5) 28 (10.9) 228 (89.1)
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be included as covariates in regression analyses; Table 2
lists these variables. Pearson’s correlations were com-
puted among behavioral economic measures (Fig. 2),
including drug supply factors (log10 past-month income,
number of heroin suppliers and unit cost), heroin-
purchasing pattern (log10 time, log10 amount and log10
frequency; percent of income spent on heroin), heroin
consumption (log10 total daily bags used) and non-heroin
expenses (percent of income spent on food, shelter/
utilities, and cigarettes). This was also done to identify
control variables for regression analyses in which we
predicted different heroin-seeking phenotypes (Table 3).
We derived a novel heroin-purchasing summary score,
‘weekly heroin investment’ [log10 purchase time ¥
purchase amount ¥ number of weekly purchases],
expressed in dollar-minutes weekly.
RESULTS
Participant characteristics
Table 1 presents BDNF genotype and allelic frequencies
for rs6265 (Met carrier versus Val/Val) for AAs (n = 74),
Table 2 Characteristics of European American participants (n = 54), by brain-derived neurotrophic factor Val66Met genotype.
Measure
Met carrier Val/Val Effect size partial
h2 (power)
c2 [1,54] or
F[1,53] (P =)n = 20 n = 34
Demographics
Gender (% male) 70 71 0.01 (0.964)
Education (years) 12.2 (0.8) 12.5 (0.5) 0.018 (0.16) 0.94 (0.336)
Estimated IQ 107.1 (7.6) 109.0 (10.4) 0.010 (0.11) 0.50 (0.481)
History of heroin use
Duration of regular use (years) 19.8 (10.9) 15.6 (9.5) 0.040 (0.30) 2.17 (0.147)
# times tried to quit 19.8 (29.5) 14.4 (24.5) 0.010 (0.11) 0.54 (0.468)
Ever overdosed (%) 45 44 0.01 (0.950)
Current heroin use
Injection use (%) 100 88 2.54 (0.111)
# suppliers 3.2 (2.0) 3.1 (1.4) 0.000 (0.05) 0.01 (0.945)
Heroin unit price ($) 10.00 (2.58) 9.74 (3.81) 0.001 (0.06) 0.08 (0.784)
Purchase time (minutes) 81.5 (66.7) 52.1 (60.8) 0.111 (0.71)a 6.52 (0.014)
Unit purchase amount ($) 46.50 (20.01) 31.77 (21.21) 0.135 (0.80)a 8.12 (0.006)
# weekly purchases 11.9 (6.3) 14.2 (9.8) 0.010 (0.11)a 0.51 (0.478)
Daily use ( # bags) 6.3 (3.4) 5.1 (3.2) 0.047 (0.35)a 2.57 (0.115)
Other recent drug use
Cigarette use (# per day) 17.9 (7.2) 13.2 (8.9) 0.073 (0.50) 4.03 (0.050)
Alcohol use (# past 30 days) 1.8 (3.6) 2.1 (3.8) 0.001 (0.06) 0.06 (0.805)
Cocaine use # past 30 days 3.0 (6.8) 5.7 (7.9) 0.031 (0.24) 1.64 (0.206)
Positive urinalysis (%) 28 68 7.53 (0.006)
Marijuana use # past 30 days 0.2 (0.5) 1.5 (4.4) 0.032 (0.25) 1.71 (0.197)
Positive urinalysis (%) 11 32 2.83 (0.092)
Past-month income/expenses
Total income ($) 2368 (1204) 1829 (1287) 0.064 (0.46)a 3.57 (0.064)
Proportion income spent on:
Heroin 76.1 (14.6) 76.5 (19.5) 0.000 (0.05) 0.01 (0.942)
Cigarettes 4.8 (3.2) 2.7 (2.9) 0.109 (0.70) 6.36 (0.015)
Food 5.3 (4.8) 5.7 (6.3) 0.001 (0.06) 0.05 (0.820)
Shelter/utilities 4.2 (6.8) 5.1 (8.2) 0.003 (0.07) 0.16 (0.693)
Lifetime DSM-IV diagnoses (%)
Antisocial personality disorder 50 (16) 20 (25)
Anxiety disorder (any type) 13 (16) 12 (25)
Major depressive disorder 31 (16) 12 (25)
Alcohol use disorder 69 (16) 64 (25)
Cocaine use disorder 63 (16) 68 (25)
Cannabis use disorder 64 (14) 36 (24)
aEffect sizes and power are for log10-transformed variables. See text. Psychiatric diagnostic data (based on SCID) were available for fewer participants than
in the overall sample. Sample sizes are shown in parentheses adjacent to each percentage for each diagnosis. Substance use disorders refer to meeting
criteria for lifetime abuse or dependence. Antisocial personality disorder refers to cases that also met criteria for childhood conduct disorder. Due to the
smaller group sizes for DSM-IV diagnoses, statistical differences were not evaluated. DSM-IV = Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition; IQ = intelligence quotient
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EAs (n = 54) and overall sample (n = 128). Genotype
frequencies for rs6265 did not deviate significantly
from Hardy–Weinberg equilibrium in the European- or
African-descent groups or the overall sample. Allele fre-
quencies significantly differed between races, with the
Met allele extremely rare in AA. Separate analyses were
performed for EAs and AAs. For the present purposes, we
primarily report results for EAs and include data for AAs
in the supplementary materials.
BDNF Val66Met effect on drug-seeking/use
Univariate analyses
Some continuous measures of heroin-seeking and
income were not normally distributed. Figure 1 shows
the distributions of responding by BDNF rs6265 geno-
type (Met carriers versus Val homozygotes) for three
primary heroin-seeking phenotypes: typical purchase
time (minute), average purchase amount (dollars),
number of weekly purchases and an empirically derived
index referred to as ‘weekly heroin investment’ that
is the product of these three measures (purchase
time ¥ purchase amount ¥ weekly purchases). Figure S1
compares the distributions of these four phenotypes
in EAs and AAs. Figure 2 illustrates the covariance
among these phenotypes in EAs, while demonstrating
BDNF Val66Met genotype differences in these response
distributions.
One-way ANOVAs found significant BDNF rs6265
genotype differences such that Met carriers had longer
purchase times and higher unit purchase amounts than
Val homozygotes (see Table 2). Similar non-significant
tendencies (P’s < .15) were observed for Met carriers to
report longer duration of heroin use, more likely to inject
heroin, and more daily bags consumed. Met carriers also
reported marginally higher total past-month income.
Table S1 provides comparable data for AA subjects.
Multivariate analyses
Multivariate ANOVA (MANOVA) was used to ascertain
whether results remained significant for the four primary
outcomes (purchase time, unit purchase amount, weekly
purchases and daily bags consumed) when adjusting for
multi-collinearity among these measures (Fig. 2); the
‘heroin investment’ measure was excluded because it
was derived directly from the first three measures. The
MANOVA confirmed that the BDNF genotype effect
remained significant, Hotelling F(4,49) = 3.17, P = .022.
Stepwise multiple regression analyses were used to
determine whether Val66Met genotype and control vari-
ables predictedmeasures of heroin-seeking in the natural
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Figure 1 Response distributions for European American participants (n = 54) with means (horizontal bars) by brain-derived neurotrophic
factor rs6265 genotype [Met carriers (n = 20) versus Val homozygotes (n = 34)] for heroin-seeking phenotypes: purchase time (upper left
panel), purchase amount (upper right panel), weekly purchases (lower left panel) and the empirically derived index ‘Weekly Heroin Investment’
(lower right panel), which is the product score of purchase time ¥ purchase amount ¥weekly purchases (measured in dollar-minutes weekly).
For each measure, the log10-transformed scores are shown on the left ordinate, and the corresponding untransformed scores are illustrated
on the right ordinate. For all measures except weekly heroin purchases, Met carriers significantly differed from Val homozygotes
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Figure 2 Relationships between drug-seeking phenotypes in European American participants (total n = 54). Each panel illustrates a significant
(P < 0.05) overall correlation between two heroin-seeking phenotypes (upper left: purchase time ¥ purchase amount; upper right: purchase
time ¥weekly purchases; lower left: purchase amount ¥weekly purchases), as well as differences in the response distributions between
brain-derived neurotrophic factor (BDNF) Met allele carriers (n = 20; closed circles) and Val/Val genotype (n = 34; open circles). Lower right
panel: combined prediction of ‘weekly heroin investment’ by BDNF genotype and past-month income (see Table 3, regression analysis)
Table 3 Summary of stepwise multiple
regressions, European Americans (n = 54).
Predictors DR2
Cum.
Adjust. R2 b T value P value
Log10 heroin purchase time
BDNF rs6265 Met carrier 0.111 0.094 0.334 2.554 0.014
Log10 heroin unit purchase amount
Total past-month income 0.158 0.142 0.325 2.569 0.013
BDNF rs6265 Met carrier 0.076 0.204 0.285 2.249 0.029
Log10 number of weekly heroin purchases
Number of suppliers 0.108 0.090 0.355 2.784 0.008
Age 0.071 0.146 -0.267 -2.092 0.041
Log10 ‘Weekly Heroin Investment’ (purchase time ¥ amount ¥ frequency)
BDNF rs6265 Met carrier 0.184 0.169 0.361 2.882 0.006
Total past-month income 0.068 0.223 0.270 2.159 0.036
Log10 daily bags of heroin consumed
Total past-month income 0.483 0.473 0.655 6.637 0.0001
Age 0.040 0.503 -0.203 -2.058 0.045
DR2 refers to unadjusted change in variance accounted for by the individual predictor variable.
Cum. Adjust. R2 refers to the cumulative (stepwise) adjusted variance accounted for. b refers to the
standardized beta coefficient. t-Test residual degrees of freedom in steps 1 and 2 of all models above
are 52 and 51, respectively. BDNF = brain-derived neurotrophic factor.
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environment. Initial analyses were stratified by ancestral
race (EA versus AA), after we determined this factor
explained significant variance on some measures. In
AAs, the infrequent Met allele was not related to any
heroin-seeking measure but due to its rarity, there was
little power in the AA sample to detect such an effect.
Thus, final regression analyses focused on EAs. Covari-
ates in all these analyses were age, number of heroin
suppliers, current injection heroin use and total past-
month income.
Table 3 shows that, in EAs (n = 54), BDNF Met allele
carriers (n = 20) had significantly longer heroin-
purchasing times and higher purchase amounts than Val
homozygotes (n = 34), which accounted for 11.1% and
7.6% of variance in these outcomes, respectively. BDNF
Met carriers had significantly higher ‘weekly heroin
investment’ scores than Val homozygotes (see Fig. 1),
which accounted for 18.4% of variance in this measure.
Higher total incomewas the primary significant predictor
of greater heroin unit purchase amounts and daily bags
consumed (explaining 15.8% and 48.3% of variance in
these two measures, respectively), whereas income was a
secondary predictor of the ‘weekly heroin investment’
score (6.8%, in contrast to 18.4% explained by BDNF
genotype; see lower right panel of Fig. 2 and Table 3).
In parallel regression analyses, BDNF genotype was
not significantly related to number of weekly heroin pur-
chases or number of daily bags consumed. Rather, the
number of weekly purchases was higher for subjects with
more heroin suppliers and those who were younger
(explaining 10.8% and 7.1% of the incremental vari-
ance, respectively).
BDNF Val66Met genotype and cigarette/nicotine use
Prevalence of smoking is very high among heroin-
dependent individuals, including this sample, providing
the opportunity to examine whether BDNF genotype
impacts this other stable form of (legal) drug use. The
influence of BDNF genotype on cigarette purchasing and
use was examined in EAs (n = 54). Eighty-seven percent
reported daily cigarette use.Two stepwisemultiple regres-
sions (which included non-smoking participants) were
used topredict theproportionof past-month incomespent
on cigarettes and the number of cigarettes smoked daily
(BDNFgenotypegroups significantlydiffered inunivariate
analyses; see Table 2), controlling for age, route of heroin
use, total past-month income and daily bags of heroin
consumed. Relative to Val homozygotes, Met carriers
reported spending a significantly higher proportion of
income on cigarettes (standardized b = 0.33, t = 2.52,
adjusted r2 = 0.092) and smoking significantlymore ciga-
rettes daily (standardized b = 0.27, t = 2.01, adjusted
r2 = 0.073). No other predictors were significant.
DISCUSSION
The BDNF 66Met allele has been repeatedly associated
with neurobehavioral deficits, including hippocampal
and frontal-cortical volume loss, and impaired learning/
memory. The Met allele leads to less BDNF secretion and
reduced neurotrophic influence, which may decrease
organismic behavioral flexibility or adaptive fitness. In
this study, we theorized that the 66Met allele may confer
resistance to environmentally or pharmacologically induced
changes in drug-seeking, or reduced behavioral flexibility,
once addictive behavior has progressed to a chronic stage.
To test this hypothesis, we assessed several related
phenotypes using a validated semi-structured interview
method to assess past-month drug-seeking/use.
Consistent with previous large population-based data,
Met allele frequency was much greater among our
European-ancestral than African-ancestral subjects
(21% versus 3%). Important to recognize is that prior
associations between BDNF Val66Met genotype and neu-
robehavioral deficits were observed exclusively among
European/Caucasian samples, where the Met allele is
more informative.
Among EAs in this study, the 66Met allele was signifi-
cantly associated with increases in several drug-seeking
behaviors. Bivariate relationships betweenVal66Met geno-
type and drug-seeking/use were initially observed for
heroin purchase time, purchase amount and an empiri-
cally derived ‘weekly heroin investment’ score (purchase
time ¥ amount ¥ weekly frequency); effect sizes were
moderate. In stepwise multiple regression analyses that
controlled for other factors that showed zero-order corre-
lations with the BDNF genotype (younger age, higher
income, more heroin suppliers and injection route of
heroin use), these bivariate relationships remained sig-
nificant.A significant genotype effectwasnot observed for
number of weekly purchases or daily bags of heroin con-
sumed.Val66Met genotype accounted for unique variance
(change in r2 value) of 7.6%, 11.1% and 18.4% in heroin
unit purchase amount, purchase time and weekly heroin
investment, respectively. Thus, BDNF Val66Met genotype
wasmore closely related to measures of drug-seeking than
consumption. This is critical for selecting an appropriate
phenotype: heroin and other illegal drug users (including
many in our sample) often obtain some drug free (e.g.
shared by others at no cost), or through bartering (e.g.
providing sex or transportation for drugs).These behavior
patterns were assessed in our interview because we noted
in our validation studies the potential for dissociation
between drug-seeking and drug consumption.
Chen et al. (2006) generated a transgenic mouse
model of the BDNF Val66Met polymorphism. Met-
homozygous animals—who exhibit 50% lower BDNF
levels and ª30% less activity-dependent BDNFMet release
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from neurons—demonstrate greater anxiety- and
depression-like behaviors (without alterations in locomo-
tion), and loss of hippocampal volume and less dendritic
complexity in dentate gyrus neurons. Thus, it may be
useful to test associations with addictive behavior in this
model. We predict that in mice trained to self-administer
heroin-like opioids, Met/Met (versus Val/Val) mice would
exhibit higher breakpoints, be less responsive to medica-
tion and environmental-incentive induced disruptions of
this behavior, and reinstate (following extinction) opioid
self-administration more readily.
A limitation of this study is that the sample size was
rather small, so hypotheses related to epistatic effects
could not be tested with adequate statistical power. The
preliminary results of this study are thus hypothesis gen-
erating, given the large number of tests performed on key
phenotypes (which exhibited multi-collinearity with one
another) and control variables, and—despite surviving
multivariate adjustment—need to be confirmed. Never-
theless, we believe that several of these results are likely
correct due to BDNF’s biological plausibility as a potential
mediator or moderator of addictive behavioral processes.
Specifically, there is growing evidence that BDNF is
involved in behavioral sensitization following repeated
exposure to abused drugs including opioids. For instance,
BDNF interacts closely with the dopamine D3 autorecep-
tor (DRD3; Le Foll et al. 2005), which controls phasic
dopamine activity (Sokoloff et al. 2006) and is implicated
in conditioned drug-seeking behavior (Everitt & Robbins
2000). Striatal BDNF/DRD3 interactions could be one
candidate mechanism by which drug-seeking is sensi-
tized and instantiated as habitual behavior (Vanders-
churen & Kalivas 2000; Gerdeman et al. 2003). This
suggests important avenues for research, including
whether dopamine polymorphisms could act in epistasis
with BDNF to modulate drug-seeking.
Given the potentially widespread neurotrophic influ-
ence of BDNF, an important question concerns the gener-
ality of its effects (behavioral specificity). In this study, we
observed in EAs that BDNF Val66Met genotype also
accounted for 9.2% of variance in purchasing (percent of
income spent) and 7.3% of variance in use (daily number)
of cigarettes. These findings in our predominantly male
subject sample are consistent with a study of nicotine-
dependent smokers (Beuten et al. 2005) and a recent large-
scale genome-wide association study (The Tobacco and
Genetics Consortium 2010). Although an association of
Val66Metwith smoking severity was not found in the study
of Beuten et al., a haplotype showed a significant relation-
ship in male EA smokers, but not female EAs or AA
smokers. Other evidence points to a role of BDNF, D3 and
D1 receptor polymorphisms in nicotine addiction, specifi-
cally with quantity of tobacco smoked (Novak et al. 2010).
The BDNF Val66Met genotype thus seems to produce an
effect on drug-seeking/use in EA populations that is
broader than for one particular class of abused substances
and may therefore be of general importance to addiction.
On the other hand, urinalysis and self-report data
were collected at screening to ascertain recent use of
drugs besides opioids. Results indicated that relative to
BDNF Val homozygotes, significantly fewerMet allele car-
riers tested positive for cocaine. A similar non-significant
trendwas observed for cannabis use.This finding does not
support the idea that the BDNF Met allele is related to
generally greater substance use. Rather, these data are
consistent with the hypothesis that theMet allele is a risk
factor for promoting the engrained use of preferred
drugs—in this case, heroin and cigarettes.
Given the present preliminary findings and published
data, our working hypothesis is that the 66Met allele,
which leads to decreased BDNF secretion and less neuro-
adaptation due to lower rates of cell proliferation, impairs
behavioral flexibility once drug self-administration
becomes habitual. This neurotrophic environment may
promote a range of neurobehavioral deficits.With specific
regard to addiction, reduced BDNF function and its
sequelae may strengthen reinforcing efficacy of preferred
drugs relative tonon-drugalternatives or despite pharma-
cotherapy. In short, selected forms of drug-seeking behav-
iormay become entrenched andmore resistant to change
in BDNF Met carriers. We found reliable 66Met genotype
differences across opioid-seeking phenotypes (i.e.
increased purchase timeand increased purchase amount)
and across drug classes (greater opioid and nicotine use).
Taken together with prior findings, the robust effects of
this genotype may implicate its broader importance for
understanding and treating addictive behavior and
underlying processes such as impairments in learning/
memory. If results of future work confirm the influence of
this neurotrophic genotype, 66Met allele carriers might
require higher levels of intervention (e.g. cognitive behav-
ior therapy or pharmacotherapy) to overcome their
chronic drug use pattern. Although we observed behav-
ioral effects of theVal66Metgenotype in a restricted sample
(small in size and primarily for EAs), this converging
pattern of association increases confidence that the
results are meaningful. Further research could be theo-
retically and clinically useful by determiningwhether this
hypothesis applies to the habitual use of other substances.
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